Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03505125 · ClinicalTrials.gov registry record
A Non-Interventional Interview Study of Phenylketonuria (PKU) Adults
A clinical trial of Phenylketonuria (PKU), sponsored by BioMarin Pharmaceutical.
- Completed
- Registry status
- 63
- Enrollment target
- 14
- Study locations
NCT03505125 is a study of Phenylketonuria (PKU) that has completed, run by BioMarin Pharmaceutical. The registered enrollment target is 63 participants, below the 172-participant average among 6 other Phenylketonuria (PKU) trials with a reported enrollment target (63% lower). The trial reports 14 study locations across 10 states.
The verdict
NCT03505125, a study of Phenylketonuria (PKU), has completed, sponsored by BioMarin Pharmaceutical.
- COMPLETED
- Registry status
- 63 participants
- Enrollment target
- 14
- Study locations
Study Summary
The 165-901 study is designed to identify the appropriate tools for use in future interventional studies on the neurocognitive effects of pegvaliase on adults with PKU.
Conditions Studied
Study Locations (14)
Other
- Rheumatology Unit, Clinic for Inborn Errors of Metabolism - Leipzig
- Hospital of Padova - Padua
- Umberto I Polyclinic of Rome - Roma
- Hacettepe University - Ankara
- Ege University School of Medicine - Izmir
Florida
- University of Florida - Gainesville
Georgia
- Emory University Department of Human Genetics - Decatur
Illinois
- Ann and Robert H Lurie Children's Hospital - Chicago
Massachusetts
- Boston Children's Hospital - Boston
British Columbia
- Adult Metabolic Diseases Clinic, Vancouver General Hospital - Vancouver
Cedex 15
- Necker Children's Hospital - Paris
Cedex 9
- Bretonneau Hospital, Internal Medicine Department - Tours
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2018-03-31 |
| Est. Completion | 2019-07-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03505125
The ClinicalTrials.gov registry entry for NCT03505125 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 172-participant average among 6 other Phenylketonuria (PKU) trials with a reported enrollment target (63% lower). The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Phenylketonuria (PKU) appearing as the primary indexed condition, and to 0 interventions.
NCT03505125 reports 14 study locations spanning 10 distinct geographic areas - top geographies include Other, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT03505125 about?
NCT03505125 is a clinical study titled "A Non-Interventional Interview Study of Phenylketonuria (PKU) Adults". The 165-901 study is designed to identify the appropriate tools for use in future interventional studies on the neurocognitive effects of pegvaliase on adults with PKU.
What is the current status of trial NCT03505125?
This trial is currently completed. The enrollment target is 63 participants. The study started on 2018-03-31. Estimated completion is 2019-07-31.
What conditions does trial NCT03505125 study?
This clinical trial studies the following conditions: Phenylketonuria (PKU).
Who is sponsoring clinical trial NCT03505125?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03505125 being conducted?
This trial has 14 study locations across Florida, Georgia, Illinois, Massachusetts, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Phenylketonuria (PKU)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)
RECRUITING
-
A Phase 2 Study of JNT-517 in Adolescent Participants With Phenylketonuria
RECRUITING · Phase 2
-
A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)
RECRUITING
-
AAV Gene Therapy Study for Subjects with PKU
ACTIVE NOT RECRUITING · Phase 1
-
Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.